Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Atezolizumab (Tecentriq, Roche) has a marketing authorisation for 'the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible'.

The dosage schedule is available in the summary of product characteristics.

The price of a 1,200‑mg vial of atezolizumab is £3,807.69 excluding VAT (company submission).

The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.